NUMIF: AI 评分 38/100 — AI 分析 (4月 2026)

Numinus Wellness Inc. is focused on developing and delivering psychedelic-assisted psychotherapy. The company operates through Salvation Botanicals, offering laboratory services, and Numinus Health, providing therapies for mental health and substance abuse.

Key Facts: AI Score: 38/100 Sector: Healthcare

公司概况

概要：

Numinus Wellness Inc. provides psychedelic-assisted psychotherapy solutions, operating through its Salvation Botanicals division for laboratory services and Numinus Health for therapeutic services. The company aims to transform the mental health landscape with a focus on psychotherapy, counseling, and substance abuse treatment.

NUMIF是做什么的？

Numinus Wellness Inc., headquartered in Vancouver, Canada, is dedicated to transforming the mental health landscape through the development and delivery of psychedelic-assisted psychotherapy. The company operates through two primary divisions: Salvation Botanicals and Numinus Health. Salvation Botanicals provides laboratory services, including cultivation, analytical testing, product research and development, and ancillary services related to psychedelics. It also offers comprehensive testing services for cannabis. Numinus Health focuses on providing supportive therapies and technologies aimed at healing, connection, and personal growth, with a particular emphasis on treating mental health and substance abuse. This division offers a range of services, including psychotherapy, counseling, neurofeedback, physiotherapy, and other therapies. Furthermore, Numinus Health provides training, facilities, and operational resources to practitioners in the field. The company's holistic approach aims to integrate psychedelic-assisted therapy with traditional mental health treatments, addressing a growing need for innovative solutions in mental healthcare. Numinus Wellness Inc. is committed to advancing research and development in the psychedelic space, seeking to establish itself as a leader in this emerging field.

NUMIF的投资论点是什么？

Numinus Wellness Inc. presents a speculative investment opportunity in the emerging field of psychedelic-assisted psychotherapy. Key value drivers include the expansion of its Numinus Health division and the potential for increased revenue from its Salvation Botanicals laboratory services. The company's focus on mental health and substance abuse treatment aligns with growing societal needs. However, the company's negative profit margin of -207.9% and reliance on a nascent market segment pose significant risks. The high beta of 2.56 indicates substantial volatility. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are crucial for long-term growth. Investors should carefully consider the risks associated with investing in an early-stage company in a highly regulated and evolving industry.

NUMIF在哪个行业运营？

Numinus Wellness Inc. operates within the burgeoning psychedelic-assisted therapy industry, which is gaining traction as an alternative approach to mental health treatment. The market is characterized by increasing research, evolving regulatory landscapes, and growing acceptance of psychedelics for therapeutic purposes. Competitors include companies like Algernon Pharmaceuticals Inc. (ALRTF) and PharmaTher Holdings Ltd. (ANPCY), which are also exploring psychedelic-based treatments. The industry is poised for growth, driven by the rising prevalence of mental health disorders and the limitations of conventional treatments. However, regulatory uncertainties and public perception remain significant challenges.

Medical - Care Facilities

Healthcare

NUMIF有哪些增长机遇？

Expansion of Numinus Health Clinics: Numinus can expand its network of Numinus Health clinics to offer psychedelic-assisted therapy and other mental health services. The market for mental health services is substantial, with a projected value of $537.96 billion in 2030. This expansion can drive revenue growth and establish Numinus as a leading provider in the space. Timeline: Ongoing.
Increased Utilization of Salvation Botanicals: Numinus can increase the utilization of its Salvation Botanicals division by offering comprehensive testing and research services to other companies in the psychedelic and cannabis industries. The analytical testing services market is expected to reach $13.1 billion by 2029. This can generate additional revenue streams and strengthen Numinus's position in the market. Timeline: Ongoing.
Strategic Partnerships and Collaborations: Numinus can pursue strategic partnerships and collaborations with research institutions, pharmaceutical companies, and other healthcare providers to advance the development and delivery of psychedelic-assisted therapies. Collaborations can accelerate research, expand market reach, and enhance Numinus's credibility. Timeline: Ongoing.
Development of Proprietary Psychedelic Formulations: Numinus can invest in the development of proprietary psychedelic formulations and delivery methods to differentiate itself from competitors and capture a larger share of the market. The market for psychedelic drugs is expected to grow significantly in the coming years. Developing innovative formulations can provide a competitive advantage and drive revenue growth. Timeline: Ongoing.
Expansion into International Markets: Numinus can expand its operations into international markets where psychedelic-assisted therapy is legal or becoming legal. The global market for mental health services is vast, and international expansion can provide significant growth opportunities. This expansion requires careful navigation of regulatory frameworks and cultural differences. Timeline: Ongoing.

Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
Negative P/E ratio of -1.33 reflects current unprofitability, suggesting the company is investing heavily in growth and development.
Gross margin of 43.7% demonstrates the potential for profitability as the company scales its operations.
Profit margin of -207.9% highlights substantial losses, requiring careful monitoring of cash flow and operational efficiency.
Beta of 2.56 indicates high volatility compared to the market, reflecting the speculative nature of the psychedelic-assisted therapy industry.

NUMIF提供哪些产品和服务？

Provides psychedelic-assisted psychotherapy solutions.
Operates Salvation Botanicals division offering laboratory services.
Offers cultivation, analytical testing, and product research for psychedelics.
Provides full suite testing and custom testing of cannabis.
Operates Numinus Health division providing supportive therapies.
Offers services for psychotherapy, counseling, and neurofeedback.
Provides training, facilities, and operational resources to practitioners.

NUMIF如何赚钱？

Generates revenue through laboratory services provided by Salvation Botanicals.
Generates revenue through therapeutic services offered by Numinus Health.
Provides training and resources to practitioners in the mental health field.

Individuals seeking mental health and substance abuse treatment.
Practitioners in the mental health field seeking training and resources.
Companies in the psychedelic and cannabis industries requiring laboratory services.

Specialized expertise in psychedelic-assisted psychotherapy.
Integrated approach combining laboratory services and therapeutic services.
Established network of Numinus Health clinics.
Focus on research and development in the psychedelic space.

什么因素可能推动NUMIF股价上涨？

Ongoing: Expansion of Numinus Health clinic network to increase patient access.
Ongoing: Development of strategic partnerships to expand research and development capabilities.
Upcoming: Potential regulatory approvals for psychedelic-assisted therapies.
Ongoing: Increased awareness and acceptance of psychedelic-assisted therapies.
Ongoing: Expansion of Salvation Botanicals laboratory services to new clients.

NUMIF的主要风险是什么？

Potential: Regulatory hurdles and evolving legal landscape for psychedelic-assisted therapies.
Potential: Competition from other companies in the psychedelic and mental health industries.
Potential: Negative public perception and stigma associated with psychedelics.
Ongoing: Dependence on external funding and potential for dilution.
Ongoing: Limited operating history and small market capitalization.

NUMIF的核心优势是什么？

Specialized expertise in psychedelic-assisted psychotherapy.
Integrated approach combining laboratory and therapeutic services.
Established network of Numinus Health clinics.
Focus on research and development in the psychedelic space.

NUMIF的劣势是什么？

Negative profit margin and reliance on external funding.
Limited operating history and small market capitalization.
High beta indicating significant volatility.
Dependence on regulatory approvals and evolving public perception.

NUMIF有哪些机遇？

Expansion of Numinus Health clinics and services.
Increased utilization of Salvation Botanicals laboratory services.
Strategic partnerships and collaborations with research institutions.
Development of proprietary psychedelic formulations and delivery methods.

NUMIF面临哪些威胁？

Regulatory uncertainties and evolving legal landscape.
Competition from other companies in the psychedelic and mental health industries.
Potential for adverse clinical trial results.
Negative public perception and stigma associated with psychedelics.

NUMIF的竞争对手是谁？

Algernon Pharmaceuticals Inc. — Focuses on developing psychedelic compounds for stroke and other neurological conditions. — (ALRTF)
PharmaTher Holdings Ltd. — Develops psychedelic-based treatments for mental health and neurological disorders. — (ANPCY)
Charlotte's Web Holdings, Inc. — Focuses on hemp-derived CBD products. — (CHHE)
The Green Organic Dutchman Holdings Ltd. — Cultivates and sells organic cannabis products. — (FPCG)
ImmunoCellular Therapeutics, Ltd. — Develops immune-based therapies for cancer. — (IMUC)

Key Metrics

MoonshotScore: 38/100

Company Profile

CEO: Michael Tan
Headquarters: Vancouver, CA
Employees: 200
Founded: 2021

AI Insight

AI analysis pending for NUMIF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Numinus Wellness Inc. do?

Numinus Wellness Inc. operates in the healthcare sector, focusing on psychedelic-assisted psychotherapy. The company has two divisions: Salvation Botanicals, which provides laboratory services like cultivation and testing for psychedelics and cannabis, and Numinus Health, which offers therapies for mental health and substance abuse. Numinus aims to transform mental healthcare by integrating psychedelic-assisted therapy with traditional treatments, addressing a growing need for innovative solutions in the mental health space.

What do analysts say about NUMIF stock?

As of 2026-03-15, formal analyst ratings for NUMIF are not available due to its OTC listing and small market capitalization. However, key valuation metrics include a negative P/E ratio, reflecting current unprofitability, and a high beta, indicating significant volatility. Growth considerations center on the expansion of its clinic network and the potential for regulatory approvals in the psychedelic-assisted therapy space. Investors should conduct thorough due diligence and consider the speculative nature of this investment.

What are the main risks for NUMIF?

The main risks for Numinus Wellness Inc. include regulatory uncertainties surrounding psychedelic-assisted therapies, competition from other companies in the mental health and psychedelic industries, and potential negative public perception. Additionally, the company's reliance on external funding and limited operating history pose financial risks. The OTC listing also introduces risks related to liquidity and disclosure requirements. Investors should carefully assess these risks before investing in NUMIF.